What is COPD?
Chronic Obstructive Pulmonary Disease (COPD) refers to a group of diseases that cause airflow blockage and breathing-related problems. It includes emphysema, chronic bronchitis, and in some cases asthma. In the United States, tobacco use is a key factor in the development and progression of COPD, but asthma, exposure to air pollutants in the home and workplace, genetic factors, and respiratory infections also play a role. In the developing world, indoor air quality is thought to play a larger role in the development and progression of COPD than it does in the United States.
COPD Clinical Research Trials
Theravance: A Phase 3, 52 week, Randomized, Active-Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects with Chronic Obstructive Pulmonary Disease. (COPD)
Purpose: To show the effect of Nebulized TD-4208 (inhaled muscarinic antagonist) administered once daily for patients with moderate to very severe COPD.
IMPACT (CTT116855): A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI with the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease.
Purpose: The study evaluates the efficacy of fluticasone, furoate/umeclidinium, bromide/vilanterol (FF/UMEC/VI) to reduce the yearly rate of moderate and severe exacerbations (COPD flare-ups) compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD.
BI 1237.19: A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]
Purpose: The objective is to assess the effect of once daily tiotropium (Spiriva) + olodaterol (Striverdi) fixed dose combination compared to 5 �g tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbations (flare-ups) in patients with severe to very severe COPD.
ROF-MD-07: A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Roflumilast 500 mcg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS).
Purpose: To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD. Participation could last up to 58 weeks.
Patient Flyer (PDF)
ASCENT (LAS-MD-45): Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD).
Purpose: The objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations. Participation could last up to 36 months.
Pulmonary Function Testing (PFT)
For All Studies:
Qualified participants will receive study-related care, study-related exams and study-related medication at no cost. Participants may be compensated for their time and travel.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: firstname.lastname@example.org.